Senescent CD8+ T-Cell Fraction (CD8+ CD28- CD57+)
Terminally differentiated cytotoxic T-lymphocytes that have lost the CD28 co-stimulatory receptor and acquired the senescence marker CD57.
Standard vs. Optimal Reference Ranges% of CD8
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
<15% of CD8+ T-cells
General reference distribution across unselected commercial populations.
<10%
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Possesses critically shortened telomeres and irreversible loss of proliferative capacity, yet secretes high levels of pro-inflammatory SASP cytokines.
Differential Diagnosis
Elevated Levels (CD8+ CD28- CD57+ High)
- •High replicative immunosenescence (>25%)
- •Chronic CMV-driven clonal expansion
- •Accelerated biological aging
- •Poor vaccine responsiveness
Low Levels (CD8+ CD28- CD57+ Low)
- •Youthful T-cell compartment (<10%)
- •Low chronic antigenic exhaustion
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for CD8+ CD28- CD57+
- Targeted organ system imaging or functional dynamic testing related to replicative immunosenescence
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Senescent CD8+ T-Cell Fraction - The New England Journal of Medicine (2021). PMID: 34190124
- [2]CD8+ CD28- CD57+ Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35422901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Senescent CD8+ T-Cell Fraction (CD8+ CD28- CD57+) into overall healthspan optimization.